Oracea

Rocky Mountain Spotted Fever, Acinetobacter Infections, Ureaplasma Infections + 61 more
Treatment
93 FDA approvals
18 Active Studies for Oracea

What is Oracea

DoxycyclineThe Generic name of this drug
Treatment SummaryDoxycycline is a type of antibiotic used to treat a wide range of bacterial infections. It is derived from oxytetracycline and is a second-generation tetracycline, meaning it has lower levels of toxicity than the first-generation of tetracyclines. The effectiveness of doxycycline in treating an infection depends on the results of an antibiotic susceptibility test.
Vibramycin Hyclateis the brand name
image of different drug pills on a surface
Oracea Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vibramycin Hyclate
Doxycycline
1967
728

Approved as Treatment by the FDA

Doxycycline, otherwise known as Vibramycin Hyclate, is approved by the FDA for 93 uses such as Chlamydia Infections and Campylobacter Infections .
Chlamydia Infections
Campylobacter Infections
Inclusion conjunctivitis
Chlamydia Infections
Urethritis
Typhus, Endemic Flea-Borne
Communicable Diseases
Dysentery, Bacillary
Gonorrhea
Bartonella Infections
Acne Vulgaris
Q Fever
Acinetobacter Infections
Ureaplasma Infections
Communicable Diseases
Uterine Cervicitis
Primary Syphilis
Lymphogranuloma Venereum
Tularemia
Listeria infection
Skin Infections
Plasmodium Infections
Actinomycosis
Rickettsialpox
Typhus infections
Anal chlamydia infection
Genus Chlamydia
Tick-borne fever
Bacteriological Techniques
Campylobacter Infection
Staphylococcus (S.) Aureus Infection
Upper Respiratory Tract Infection
Epididymo-orchitis gonococcal
Trachoma
Neisseria Gonorrhoeae Infection
Fever
Ureaplasma urethritis
Chlamydia trachomatis
Streptococcus Pneumoniae Infections
Communicable Diseases
Rocky Mountain Spotted Fever
Severe Acne
Chlamydial Urethritis
Bartonella bacilliformis infections
Malaria
Bacterial Infection caused by Enterobacter aerogenes
Relapsing Fever
Yaws
Chancroid
Amebic colitis
Clostridium difficile Infection
Brucellosis
Used to treat Brucellosis in combination with Streptomycin
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Haemophilus Influenzae Infections
Calymmatobacterium granulomatis
Cholera (Disorder)
Chlamydial cervicitis
Plague
Chlamydia trachomatis
Secondary Syphilis
Intestinal Amebiasis
Relapsing fever caused by Borrelia recurrentis
Klebsiella Infections
Necrotizing ulcerative gingivostomatitis
Urinary Tract Infections
Mycoplasma Pneumoniae
Cat-Scratch Disease
Shigella Infection
inhaled anthrax caused by Bacillus anthracis
Pneumococcal Infections
Clostridium Infections
Common Cold
Brucellosis
Used to treat Brucellosis in combination with Streptomycin
Trachoma
Plague
Urethritis
Acinetobacter Infections
Yersinia pestis
Psittacosis
Chlamydia psitacci infection
Ureaplasma Infections
Infection Due to Escherichia Coli
Trachoma inclusion conjunctivitis
Listeriosis
Yaws
Relapsing Fever
Vibrio Cholerae Infection
Disease
Haemophilus ducreyi infection
Tularemia
prophylaxis of Malaria
Respiratory Tract Infections
Granuloma Inguinale

Effectiveness

How Oracea Affects PatientsDoxycycline is an antibiotic that helps stop the growth of bacteria, and works by preventing bacteria from making proteins. It is a lipophilic drug, meaning it can pass through multiple layers of cells, and has a wide range of effectiveness against both gram-positive and gram-negative bacteria. It also has anti-parasitic and anti-inflammatory properties, and has been used to treat various inflammatory skin conditions.
How Oracea works in the bodyDoxycycline prevents bacteria from making proteins they need to survive. It does this by blocking the molecules that attach to the ribosome of the cell, which is like a factory for making proteins. Doxycycline also stops inflammation by preventing calcium from helping create microtubules and keeping white blood cells from gathering at the site of inflammation. Additionally, it stops an enzyme that produces a molecule that causes inflammation.

When to interrupt dosage

The measure of Oracea is contingent upon the diagnosed state, including Urethritis, Chlamydia trachomatis and Respiratory Tract Infections. The dose likewise deviates in accordance with the technique of delivery (e.g. Capsule or Syrup - Oral) featured in the table underneath.
Condition
Dosage
Administration
Rocky Mountain Spotted Fever
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Ureaplasma Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Q Fever
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Acinetobacter Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Trachoma
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Yaws
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Psittacosis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Plague
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Uterine Cervicitis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Tularemia
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chancroid
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Actinomycosis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Rickettsialpox
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Tick-borne fever
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Epididymo-orchitis gonococcal
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Inclusion conjunctivitis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Typhus, Endemic Flea-Borne
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Common Cold
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chlamydia Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chlamydia trachomatis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Kit - Oral, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup, Syrup - Oral, For suspension, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Oracea Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Doxycycline may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Doxycycline may interact with Pulse Frequency
There are 20 known major drug interactions with Oracea.
Common Oracea Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Doxycycline.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Doxycycline.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Doxycycline.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Doxycycline.
Amdinocillin
Major
The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.
Oracea Toxicity & Overdose RiskThe lowest toxic dose of doxycycline in rats is 2000 mg/kg, 1870 mg/kg in mice, and 500 mg/kg in dogs. If someone overdoses on doxycycline, they should stop taking it and get medical help. Dialysis will not reduce the amount of drug in the body, so it will not help with an overdose.
image of a doctor in a lab doing drug, clinical research

Oracea Novel Uses: Which Conditions Have a Clinical Trial Featuring Oracea?

34 active studies are currently being conducted to assess the efficacy of Oracea in combating Haemophilus Influenzae Infections, Respiratory Tract Infections and Amebic Colitis.
Condition
Clinical Trials
Trial Phases
Plague
0 Actively Recruiting
Plague
0 Actively Recruiting
Epididymo-orchitis gonococcal
0 Actively Recruiting
Lymphogranuloma Venereum
0 Actively Recruiting
Gonorrhea
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Chlamydia trachomatis
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
Urethritis
0 Actively Recruiting
Typhus, Endemic Flea-Borne
0 Actively Recruiting
Clostridium difficile Infection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Chlamydia Infections
0 Actively Recruiting
inhaled anthrax caused by Bacillus anthracis
0 Actively Recruiting
Calymmatobacterium granulomatis
0 Actively Recruiting
Haemophilus Influenzae Infections
0 Actively Recruiting
Chancroid
0 Actively Recruiting
Klebsiella Infections
0 Actively Recruiting
Rosacea
2 Actively Recruiting
Early Phase 1, Phase 2
Rocky Mountain Spotted Fever
0 Actively Recruiting

Oracea Reviews: What are patients saying about Oracea?

5Patient Review
3/14/2015
Oracea for Severe Difficult to Treat Nodular Rosacea
Oracea was a godsend for me. I had been struggling with Rosacea for years and tried everything to no avail. But this medication finally helped clear up my skin and I haven't had any issues since.
5Patient Review
9/26/2013
Oracea for Severe Difficult to Treat Nodular Rosacea
Oracea has been effective for me in clearing my face. I use it together with Finacea, and it's worked well for me. The only downside is that as soon as I try to lower the dose (at least 3 times per week), all of my bumps and pimples return. It looks like I'll have to take it for as long as I can afford it!
5Patient Review
8/15/2013
Oracea for Severe Difficult to Treat Nodular Rosacea
I've been using this treatment for three months now and have definitely seen an improvement. I'm less stressed in general, and when I do get stressed, the bumps aren't as bad as they used to be.
5Patient Review
10/2/2012
Oracea for Severe Difficult to Treat Nodular Rosacea
This drug has been a complete wonder for me, it's helped with the redness of my rosacea immensely.
4.7Patient Review
3/30/2014
Oracea for Severe Difficult to Treat Nodular Rosacea
I've been using this treatment for over five years to manage my Rosacea. It's been incredibly effective; however, I have to be careful about when I eat and drink (which can be annoying). All in all, though, it's a small price to pay for such good results. I haven't been able to find any information on long-term effects but, so far, so good.
4Patient Review
1/12/2012
Oracea for Severe Difficult to Treat Nodular Rosacea
I find this to be a very effective treatment with no notable side effects. The price is high, but there are discounts available. It can take some time to work, but it's worth being patient. In my case, it worked great and I haven't experienced any issues since stopping the treatment.
2.7Patient Review
2/2/2013
Oracea for Severe Difficult to Treat Nodular Rosacea
After taking Oracea and metronidazole cream as prescribed by my dermatologist, my skin started flaking off within two days. I called the doctor and they said to stop taking the metro cream. However, after reading comments online, I now realize it was the Oracea that caused the problems. I also had an outbreak on my chest and neck and terrible itching. The allergist took me off pravastatin and the redness went away along with most of the skin problems! Why don't doctors warn you about potential side effects??????
2.3Patient Review
11/20/2012
Oracea for Severe Difficult to Treat Nodular Rosacea
I was really excited to try this treatment because my dermatologist made it sound like a total game changer for people with Rosacea. And while I did see some improvement after taking it for a few days, it wasn't worth the awful side effects I experienced. 10% just isn't enough when the cost is so high.
2.3Patient Review
1/17/2013
Oracea for Severe Difficult to Treat Nodular Rosacea
I have seen zero benefits from this pill, and my acne is actually worse than before. Additionally, it was incredibly expensive; I refused to renew the prescription after learning that one month would cost over $1,000.
2Patient Review
3/31/2013
Oracea for Severe Difficult to Treat Nodular Rosacea
After a year of use, I haven't seen any improvement in my condition. If anything, it's gotten worse.
1.7Patient Review
2/21/2012
Oracea for Severe Difficult to Treat Nodular Rosacea
My rosacea symptoms actually got worse while taking this medication. I had a few initial days where it seemed to be helping, but then things took a turn for the worse. I also experienced some pretty unpleasant side effects like diarrhea, dry eyes and blurred vision, vaginal yeast infection, itching all over my body, bloating and weight gain, dizziness, and fatigue. Overall, not a great experience.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about oracea

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Oracea?

"If you experience any of the following symptoms, you may be allergic to this medication: nausea, diarrhea, upset stomach, headache, skin rash, itching, and vaginal itching or discharge."

Answered by AI

How long should you take Oracea?

"Oracea should not be used to treat or prevent infections. Its efficacy beyond 16 weeks is unknown."

Answered by AI

What is Oracea prescribed for?

"The medication ORACEA® is only effective in treating the inflammatory lesions of rosacea, not the redness. It comes in the form of capsules, each containing 40 mg of doxycycline. ORACEA is intended for use by adult patients only."

Answered by AI

Are doxycycline and Oracea the same thing?

"ORACEA® (doxycycline, USP) 40mg* Capsules contains a low dose of doxycycline, which does not work by killing bacteria like traditional antibiotic doses."

Answered by AI

Clinical Trials for Oracea

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Oracea clinical trials? We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Waitlist Available
Has No Placebo
Children's Community Pediatrics Brentwood (+1 Sites)Timothy R Shope, MD, MPHMerck Sharp & Dohme LLC
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA
The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.
Waitlist Available
Has No Placebo
University of Pennsylvania Primary Care Practice
Have you considered Oracea clinical trials? We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.Go to Trials
Image of George Washington University Hospital in Washington, United States.

Rapid Test for Respiratory Infections

18+
All Sexes
Washington, United States
The study titled " The Effect of Definitive Identification of Viral Etiology in Emergency Department Patients with Acute Respiratory Infection on Antibiotic Utilization (RADIATE)" aims to investigate the effectiveness of a rapid diagnostic approach in reducing unnecessary antibiotic use in the emergency department (ED) for patients presenting with acute respiratory illness (ARI) due to a virus. Using a prospective design, eligible participants are individuals who visit the ED with complaints related to acute respiratory illness. The study will employ a single-arm consecutive enrollment approach. The intervention involves the implementation of a rapid point-of-care multiplex polymerase chain reaction (PCR) test to promptly identify the viral cause of the infection. By utilizing a rapid diagnostic tool to identify viral etiology, the study aims to provide healthcare professionals in the ED with more accurate information to guide treatment decisions. Ultimately, the goal is to decrease the unnecessary use of antibiotics for ARI's due to a virus, which has several negative outcomes including promotion of antibiotic resistance, exacerbating ED length of stay and encouraging unnecessary additional diagnostic tests.
Waitlist Available
Has No Placebo
George Washington University Hospital (+2 Sites)Christopher Payette, MDBioMérieux
Image of Rush University Medical Center in Chicago, United States.

Menstrual Cups for Vaginal Infections

15 - 35
Female
Chicago, IL
HIV remains a global pandemic with 37 million infected. In western Kenya, 16% of women in the general population and 29% of the poorest women have HIV. The HIV and sexually transmitted infection (STI) epidemics overlap with broader reproductive health concerns. Menstrual hygiene management is a big problem in low- and middle-income countries and a lack of menstrual products negatively impacts women's work-life. This comes from cultural taboos, stigma, and discrimination, promoting secrecy around menstruation, high cost of menstrual products, use of traditional materials (e.g. rags, cotton wool, etc.) causing leakage and odor, and lack of water and safe hygiene facilities. Menstrual cups designed for use during sex may help women prevent Bacterial vaginosis (BV) and STIs through hygienic period practices, and may help them avoid bad practices in an attempt to maintain vaginal dryness. The goal of this interventional trial is to test the impact of menstrual cups on vaginal microbiome, BV, and STIs of poor women at high risk for STIs and HIV. We predict to see 25% less BV, our primary outcome, over one year. This trial aims to learn more about the safety of the intervention, and understand what is needed to fully implement the program.
Phase 2
Waitlist Available
Rush University Medical Center
Have you considered Oracea clinical trials? We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security